Novel and emerging treatments for major depression

S Marwaha, E Palmer, T Suppes, E Cons, AH Young… - The Lancet, 2023 - thelancet.com
Depression is common, costly, debilitating, and associated with increased risk of suicide. It is
one of the leading global public health problems. Although existing available …

Ketamine and the neurobiology of depression: Toward next-generation rapid-acting antidepressant treatments

JH Krystal, AP Kaye, S Jefferson, MJ Girgenti… - Proceedings of the …, 2023 - pnas.org
Ketamine has emerged as a transformative and mechanistically novel pharmacotherapy for
depression. Its rapid onset of action, efficacy for treatment-resistant symptoms, and …

Single-dose psilocybin treatment for major depressive disorder: a randomized clinical trial

CL Raison, G Sanacora, J Woolley, K Heinzerling… - Jama, 2023 - jamanetwork.com
Importance Psilocybin shows promise as a treatment for major depressive disorder (MDD).
Objective To evaluate the magnitude, timing, and durability of antidepressant effects and …

Psilocybin desynchronizes the human brain

JS Siegel, S Subramanian, D Perry, BP Kay… - Nature, 2024 - nature.com
A single dose of psilocybin, a psychedelic that acutely causes distortions of space–time
perception and ego dissolution, produces rapid and persistent therapeutic effects in human …

Single-dose psilocybin-assisted therapy in major depressive disorder: A placebo-controlled, double-blind, randomised clinical trial

R von Rotz, EM Schindowski, J Jungwirth… - …, 2023 - thelancet.com
Background Psilocybin has been suggested as a novel, rapid-acting treatment for
depression. Two consecutive doses have been shown to markedly decrease symptom …

Human brain effects of DMT assessed via EEG-fMRI

C Timmermann, L Roseman… - Proceedings of the …, 2023 - National Acad Sciences
Psychedelics have attracted medical interest, but their effects on human brain function are
incompletely understood. In a comprehensive, within-subjects, placebo-controlled design …

Treatment‐resistant depression: definition, prevalence, detection, management, and investigational interventions

RS McIntyre, M Alsuwaidan, BT Baune, M Berk… - World …, 2023 - Wiley Online Library
Treatment‐resistant depression (TRD) is common and associated with multiple serious
public health implications. A consensus definition of TRD with demonstrated predictive utility …

Must psilocybin always “assist psychotherapy”?

GM Goodwin, E Malievskaia… - American Journal of …, 2024 - Am Psychiatric Assoc
Design Open-label Randomized Randomized, double-blind, placebo-controlled
Randomized, double-blind, placebo-controlled Randomized, double-blind, placebo …

[HTML][HTML] Single-dose psilocybin for a treatment-resistant episode of major depression: Impact on patient-reported depression severity, anxiety, function, and quality of …

GM Goodwin, ST Aaronson, O Alvarez, M Atli… - Journal of Affective …, 2023 - Elsevier
Background COMP360 is a proprietary, synthetic formulation of psilocybin being developed
for treatment-resistant depression (TRD), a burdensome, life-threatening illness with high …

Adverse events in studies of classic psychedelics: A systematic review and meta-analysis

JT Hinkle, M Graziosi, SM Nayak, DB Yaden - JAMA psychiatry, 2024 - jamanetwork.com
Importance A clear and comprehensive understanding of risks associated with psychedelic-
assisted therapy is necessary as investigators extend its application to new populations and …